Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
08:00am, Tuesday, 20'th May 2025
NEW YORK--(BUSINESS WIRE)-- #AI--VantAI, a leader in generative AI and proximity-based therapeutics, announced today that it has entered into a second expansion of its collaboration and license agreem
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
01:25pm, Friday, 02'nd May 2025
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
02:01pm, Thursday, 01'st May 2025
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communica
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates
09:26am, Thursday, 01'st May 2025
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago.
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
07:00am, Thursday, 01'st May 2025
-- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
08:00am, Friday, 25'th Apr 2025
CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
11:08am, Thursday, 24'th Apr 2025
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth
05:37am, Monday, 07'th Apr 2025
Blueprint Medicines' focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other promi
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
08:00am, Monday, 31'st Mar 2025
CAMBRIDGE, Mass. , March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annua
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
08:00am, Friday, 28'th Feb 2025
-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
03:01pm, Friday, 14'th Feb 2025
Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
11:32am, Thursday, 13'th Feb 2025
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President
Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates
09:25am, Thursday, 13'th Feb 2025
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago.
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
07:00am, Thursday, 13'th Feb 2025
-- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approxi
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know
11:05am, Thursday, 06'th Feb 2025
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
